{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:37:24Z","timestamp":1759667844330},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European Union's Horizon"},{"name":"Marie Sk\u0142odowska-Curie","award":["665735"],"award-info":[{"award-number":["665735"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.yexcr.2017.04.003","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T22:16:31Z","timestamp":1491430591000},"page":"162-171","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nitric oxide donor augments antineoplastic effects of arginine deprivation in human melanoma cells"],"prefix":"10.1016","volume":"355","author":[{"given":"Oksana","family":"Mayevska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena","family":"Karatsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaroslav","family":"Bobak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryna","family":"Barska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Lyniv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliia","family":"Pavlyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriy","family":"Rzhepetskyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Igumentseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jolanta","family":"Redowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleh","family":"Stasyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2017.04.003_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2340\/00015555-2035","article-title":"Metastatic melanoma - a review of current and future treatment options","volume":"95","author":"Maverakis","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/jocmr2424w","article-title":"Novel drugs and combination therapies for the treatment of metastatic melanoma","volume":"8","author":"Vennepureddy","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.yexcr.2017.04.003_bib3","first-page":"11","article-title":"Arginine deprivation therapy for malignant melanoma","volume":"5","author":"Yoon","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib4","doi-asserted-by":"crossref","first-page":"17665","DOI":"10.18632\/oncotarget.6882","article-title":"BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2017.04.003_bib5","first-page":"5443","article-title":"Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo","volume":"62","author":"Ensor","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2017.04.003_bib6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/bjc.2012.106","article-title":"Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase","volume":"106","author":"Feun","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexcr.2017.04.003_bib7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature15529","article-title":"Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis","volume":"527","author":"Rabinovich","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2017.04.003_bib8","doi-asserted-by":"crossref","first-page":"7660","DOI":"10.1200\/JCO.2005.02.0933","article-title":"Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies","volume":"23","author":"Ascierto","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10637-012-9862-2","article-title":"Phase I\/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma","volume":"31","author":"Ott","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.yexcr.2017.04.003_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2015.04.020","article-title":"Targeting arginine metabolism pathway to treat arginine-dependent cancers","volume":"364","author":"Qiu","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2017.04.003_bib11","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.18632\/oncotarget.3370","article-title":"Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin","volume":"6","author":"Savaraj","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2017.04.003_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cbin.10383","article-title":"Recombinant arginine-degrading enzymes in metabolic anticancer therapy and bioanalytics","volume":"39","author":"Stasyk","year":"2015","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.yexcr.2017.04.003_bib13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4236\/ojmip.2012.23014","article-title":"Nitric oxide \u2013 important messenger in human body","volume":"2","author":"Antosova","year":"2012","journal-title":"Open J. Mol. Integr. Physiol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbrc.2013.01.041","article-title":"Applications for nitric oxide in halting proliferation of tumor cells","volume":"431","author":"Reynolds","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2017.04.003_bib15","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0006-2952(03)00555-0","article-title":"Recombinant arginine deiminase as a differential modulator of inducible (iNOS) and endothelial (eNOS) nitric oxide synthetase activity in cultured endothelial cells","volume":"66","author":"Shen","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib16","first-page":"248","article-title":"Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production","volume":"8","author":"Dillon","year":"2002","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.yexcr.2017.04.003_bib17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/bj3630581","article-title":"Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor \u03b1 and endotoxin","volume":"363","author":"Thomas","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.yexcr.2017.04.003_bib18","first-page":"67","article-title":"Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma","volume":"12","author":"Stelter","year":"2013","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.yexcr.2017.04.003_bib19","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1200\/JCO.2004.11.120","article-title":"Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I\/II studies","volume":"22","author":"Izzo","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib20","doi-asserted-by":"crossref","first-page":"e88639","DOI":"10.1371\/journal.pone.0088639","article-title":"Reduction of death rate due to acute myocardial infarction in subjects with cancers through systemic restoration of impaired nitric oxide","volume":"9","author":"Ghosh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2017.04.003_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/carcin\/bgt034","article-title":"The yin and yang of nitric oxide in cancer progression","volume":"34","author":"Burke","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yexcr.2017.04.003_bib22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.redox.2015.08.013","article-title":"Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics","volume":"6","author":"Bonavida","year":"2015","journal-title":"Redox Biol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I","article-title":"Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis","volume":"86","author":"Jadeski","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2017.04.003_bib24","first-page":"275","article-title":"Nitric oxide decreases motility and increases adhesion in human breast cancer cells","volume":"21","author":"Lahiri","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.yexcr.2017.04.003_bib25","first-page":"186972","article-title":"Long-term nitric oxide exposure enhances lung cancer cell migration","author":"Sanuphan","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.yexcr.2017.04.003_bib26","unstructured":"Cell lines by genetic mutations. Available from: \u3008https:\/\/www.lgcstandards-atcc.org\u3009."},{"key":"10.1016\/j.yexcr.2017.04.003_bib27","unstructured":"Melanoma cell lines grouped for BRAF\/-N-ras\/PTEN\/CDK4 mutations Available from: \u3008https:\/\/www.wistar.org\u3009."},{"key":"10.1016\/j.yexcr.2017.04.003_bib28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/CAD.0b013e32833e0334","article-title":"Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells","volume":"22","author":"Vynnytska","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.yexcr.2017.04.003_bib29","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/ijc.26221","article-title":"Single amino acid arginine starvation efficiently sensitizes cancer cells to canavanine treatment and irradiation","volume":"130","author":"Vynnytska-Myronovska","year":"2012","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.yexcr.2017.04.003_bib30","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00726-014-1857-1","article-title":"Arginine deprivation specifically affects glioblastoma cell migration, adhesion, invasiveness and actin cytoskeleton organization","volume":"47","author":"Pavlyk","year":"2015","journal-title":"Amino Acids"},{"key":"10.1016\/j.yexcr.2017.04.003_bib31","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1042\/CBI20100451","article-title":"Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes","volume":"34","author":"Bobak","year":"2010","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.yexcr.2017.04.003_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.30970\/sbi.0502.155","article-title":"Effect of nitric oxide donor on viability of human leukemic cells upon arginine deprivation","volume":"5","author":"Chen","year":"2011","journal-title":"Stud. Biol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1096\/fj.06-7859rev","article-title":"Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival","volume":"22","author":"Junttila","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.yexcr.2017.04.003_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10059-013-0138-2","article-title":"Nutrient regulation of the mTOR complex 1 signaling pathway","volume":"35","author":"Kim","year":"2013","journal-title":"Mol. Cells"},{"key":"10.1016\/j.yexcr.2017.04.003_bib35","first-page":"17","article-title":"Cell sensitivity assays: clonogenic assay","volume":"28","author":"Plumb","year":"1999","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.yexcr.2017.04.003_bib36","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a005074","article-title":"Integrins in cell migration","volume":"3","author":"Huttenlocher","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib37","unstructured":"N.M. Cheng, Y.C. Leung, W.H. Lo, US Patent No. 20050244398. 5, 2005."},{"key":"10.1016\/j.yexcr.2017.04.003_bib38","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.44","article-title":"Nitric oxide for cancer therapy","author":"Huerta","year":"2015","journal-title":"Future Sci."},{"key":"10.1016\/j.yexcr.2017.04.003_bib39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4103\/0970-9185.142799","article-title":"Sodium nitroprusside in 2014: a clinical concepts review","volume":"30","author":"Hottinger","year":"2014","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ijc.21767","article-title":"Tumor iNOS predicts poor survival for stage III melanoma patients","volume":"4","author":"Ekmekcioglu","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2017.04.003_bib41","doi-asserted-by":"crossref","first-page":"22950","DOI":"10.1038\/srep22950","article-title":"Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)","volume":"6","author":"Burrows","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexcr.2017.04.003_bib42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2174\/138920011797470092","article-title":"Dual function of nitric oxide in carcinogenesis, reappraisal","volume":"12","author":"Engin","year":"2011","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib43","first-page":"909","article-title":"Nitric oxide donors: novel cancer therapeutics (review)","volume":"33","author":"Huerta","year":"2008","journal-title":"Int J. Oncol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.yexcr.2017.04.003_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ijc.30051","article-title":"Molecular basis and current strategies of therapeutic arginine depletion for cancer","volume":"139","author":"Fultang","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2017.04.003_bib46","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.yexcr.2017.04.003_bib47","doi-asserted-by":"crossref","first-page":"e0132655","DOI":"10.1371\/journal.pone.0132655","article-title":"VS-5584, a novel PI3K-mTOR dual inhibitor, inhibits melanoma cell growth in vitro and in vivo","volume":"10","author":"Shao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2017.04.003_bib48","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-4598-9-7","article-title":"Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexcr.2017.04.003_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00133592","article-title":"Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential","volume":"4","author":"Updyke","year":"1986","journal-title":"Clin. Ex. Metastas"},{"key":"10.1016\/j.yexcr.2017.04.003_bib50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0304-3835(96)04112-2","article-title":"Apoptosis and metastasis: a superior resistance of metastatic cancer cells to programmed cell death","volume":"101","author":"Glinsky","year":"1996","journal-title":"Cancer Lett."},{"key":"10.1016\/j.yexcr.2017.04.003_bib51","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/ar.22969","article-title":"Protein arginylation, a global biological regulator that targets actin cytoskeleton and the muscle","volume":"297","author":"Kashina","year":"2014","journal-title":"Anat. Rec. (Hoboken)"},{"key":"10.1016\/j.yexcr.2017.04.003_bib52","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1016\/j.febslet.2007.07.015","article-title":"Variable actin dynamics requirement for the exit of different cargo from the trans-Golgi network","volume":"581","author":"Lazaro-Dieguez","year":"2007","journal-title":"FEBS Lett."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482717302033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482717302033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T01:51:49Z","timestamp":1601862709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482717302033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0014482717302033"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2017.04.003","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitric oxide donor augments antineoplastic effects of arginine deprivation in human melanoma cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2017.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}